ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
garthhunt
|
1.0K |
413K |
8 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
413K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
garthhunt
|
1.0K |
413K |
64 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
413K
|
64
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
garthhunt
|
1.3K |
570K |
44 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
1.3K
|
570K
|
44
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
garthhunt
|
274 |
125K |
6 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
274
|
125K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
garthhunt
|
914 |
300K |
7 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
300K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Q3 Financial Results Webcast
|
|
garthhunt
|
300 |
87K |
2 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
300
|
87K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
garthhunt
|
18K |
7.1M |
5 |
11/05/21 |
11/05/21 |
ASX - By Stock
|
18K
|
7.1M
|
5
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
garthhunt
|
10K |
3.1M |
2 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
10K
|
3.1M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
garthhunt
|
1.6K |
470K |
0 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
470K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
garthhunt
|
1.6K |
470K |
6 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
470K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
garthhunt
|
1.6K |
470K |
2 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
470K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
garthhunt
|
115 |
35K |
6 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
115
|
35K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
garthhunt
|
1.6K |
470K |
5 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
470K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
garthhunt
|
1.6K |
470K |
14 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
470K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
garthhunt
|
1.6K |
470K |
16 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
470K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group
|
|
garthhunt
|
508 |
175K |
9 |
02/03/21 |
02/03/21 |
ASX - By Stock
|
508
|
175K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
garthhunt
|
272 |
140K |
22 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
272
|
140K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
garthhunt
|
1.1K |
322K |
5 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
322K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
garthhunt
|
1.1K |
322K |
46 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
322K
|
46
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
garthhunt
|
10K |
3.1M |
7 |
14/01/21 |
14/01/21 |
ASX - By Stock
|
10K
|
3.1M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
garthhunt
|
763 |
329K |
7 |
14/01/21 |
14/01/21 |
ASX - By Stock
|
763
|
329K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
garthhunt
|
763 |
329K |
8 |
13/01/21 |
13/01/21 |
ASX - By Stock
|
763
|
329K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
garthhunt
|
763 |
329K |
13 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
763
|
329K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
garthhunt
|
763 |
329K |
2 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
329K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
garthhunt
|
183 |
95K |
28 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
95K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
garthhunt
|
183 |
95K |
12 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
95K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
garthhunt
|
183 |
95K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
95K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
garthhunt
|
1.0K |
524K |
19 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
524K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
garthhunt
|
13K |
5.0M |
0 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
garthhunt
|
192 |
87K |
2 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
192
|
87K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
garthhunt
|
1.0K |
425K |
16 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
1.0K
|
425K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
garthhunt
|
1.0K |
425K |
4 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
1.0K
|
425K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Immortal Time Bias - Deceased Control Patients Can’t Be Hospitalized
|
|
garthhunt
|
27 |
9.8K |
2 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
27
|
9.8K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Immortal Time Bias - Deceased Control Patients Can’t Be Hospitalized
|
|
garthhunt
|
27 |
9.8K |
5 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
27
|
9.8K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Immortal Time Bias - Deceased Control Patients Can’t Be Hospitalized
|
|
garthhunt
|
27 |
9.8K |
4 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
27
|
9.8K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
garthhunt
|
1.0K |
425K |
46 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
425K
|
46
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
garthhunt
|
1.0K |
425K |
34 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
425K
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
garthhunt
|
1.0K |
425K |
20 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
425K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
garthhunt
|
1.0K |
425K |
58 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
425K
|
58
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
garthhunt
|
416 |
134K |
6 |
14/12/20 |
14/12/20 |
ASX - By Stock
|
416
|
134K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
garthhunt
|
13K |
5.0M |
7 |
10/12/20 |
10/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
garthhunt
|
13K |
5.0M |
4 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
garthhunt
|
13K |
5.0M |
5 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
garthhunt
|
13K |
5.0M |
32 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
32
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
garthhunt
|
811 |
341K |
0 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
341K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
garthhunt
|
811 |
341K |
4 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
341K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
garthhunt
|
811 |
341K |
5 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
341K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
garthhunt
|
811 |
341K |
4 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
341K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
garthhunt
|
811 |
341K |
3 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
341K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
garthhunt
|
811 |
341K |
9 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
341K
|
9
|
|